CVS Health is raising eyebrows with a new estimate: A coming class of pricey cholesterol meds could cost the U.S. as much as $150 billion per year.
Gilead's got a message for you, AbbVie: It's on. Just a couple of weeks after the Illinois drugmaker struck an exclusive hep C pact with PBM Express Scripts, Gilead has come back with a deal of its own.
In the evolving drug payer world, pharmacy benefit managers (PBM) are commanding a bigger role. Now drug companies have a new and interesting PBM with which to contend--Costco.
Beginning in January, the list of drugs CVS Caremark's pharmacy-benefit business will refuse to cover will grow to about 50.
CVS Caremark and Rite Aid have signed on to the Effexor XR conspiracy theory. In an antitrust lawsuit, the drugstore chains allege that Pfizer's Wyeth unit and Teva Pharmaceutical Industries colluded to delay generic versions of the blockbuster antidepressant.
Drugmakers, prepare for attack. CVS Caremark is fed up with your new favorite marketing technique: the co-pay card.
It had to happen eventually: A pharmacy benefits manager is striking back at co-pay coupons. As The Wall Street Journal reports, CVS Caremark's PBM is recommending that customers stop covering 34
Who's picking up the Tylenol slack? Private store brands--and the drugmakers that supply them. In the wake of a series of Johnson & Johnson (NYSE: JNJ) consumer-drug recalls, retailers are